Patient baseline characteristics
| Characteristic . | All patients (N = 35) . |
|---|---|
| Age, y | |
| Median (range) | 55 (20-80) |
| Sex, n (%) | |
| Male | 19 (54) |
| Female | 16 (46) |
| ECOG score, median (range) | 1 (0-3) |
| ALL cytogenetic characteristics, n (%) | |
| Philadelphia chromosome | 4 (11) |
| MLL rearrangement | 0 (0) |
| E2A-PBX1 | 1 (3) |
| TEL-AML1 | 0 (0) |
| IL3-IGH | 1 (3) |
| Hyperdiploid >50 | 1 (3) |
| Hypodiploid | 3 (9) |
| Other (mixed/unknown) | 25 (71) |
| Disease status at enrollment, n (%) | |
| Primary refractory | 6 (17) |
| Relapsed | 29 (83) |
| Extramedullary involvement, n (%) | |
| Yes | 2 (6) |
| No | 33 (94) |
| Number of prior systemic therapies,*median (range) | 3 (1-15) |
| 1, n (%) | 4 (11) |
| 2, n (%) | 8 (23) |
| 3, n (%) | 8 (23) |
| ≥4, n (%) | 15 (43) |
| Prior B cell–directed therapies, n (%) | |
| Blinatumomab | 16 (46) |
| Inotuzumab ozogamicin | 6 (17) |
| Rituximab | 6 (17) |
| CAR-T | 2 (6) |
| Ofatumumab | 1 (3) |
| Prior HSCT, n (%) | |
| Allogeneic | 11 (31) |
| Autologous | 2 (6) |
| Characteristic . | All patients (N = 35) . |
|---|---|
| Age, y | |
| Median (range) | 55 (20-80) |
| Sex, n (%) | |
| Male | 19 (54) |
| Female | 16 (46) |
| ECOG score, median (range) | 1 (0-3) |
| ALL cytogenetic characteristics, n (%) | |
| Philadelphia chromosome | 4 (11) |
| MLL rearrangement | 0 (0) |
| E2A-PBX1 | 1 (3) |
| TEL-AML1 | 0 (0) |
| IL3-IGH | 1 (3) |
| Hyperdiploid >50 | 1 (3) |
| Hypodiploid | 3 (9) |
| Other (mixed/unknown) | 25 (71) |
| Disease status at enrollment, n (%) | |
| Primary refractory | 6 (17) |
| Relapsed | 29 (83) |
| Extramedullary involvement, n (%) | |
| Yes | 2 (6) |
| No | 33 (94) |
| Number of prior systemic therapies,*median (range) | 3 (1-15) |
| 1, n (%) | 4 (11) |
| 2, n (%) | 8 (23) |
| 3, n (%) | 8 (23) |
| ≥4, n (%) | 15 (43) |
| Prior B cell–directed therapies, n (%) | |
| Blinatumomab | 16 (46) |
| Inotuzumab ozogamicin | 6 (17) |
| Rituximab | 6 (17) |
| CAR-T | 2 (6) |
| Ofatumumab | 1 (3) |
| Prior HSCT, n (%) | |
| Allogeneic | 11 (31) |
| Autologous | 2 (6) |
HSCT, hematopoietic stem cell transplantation; MLL, mixed lineage leukemia.
Prior stem cell transplantation is included. For patients who underwent autologous transplantation, the mobilization regimen was considered a line of therapy if it was chemotherapy based and distinct from the other previous lines of treatment.